Differential Bonding Interactions of Inverse Agonists of Angiotensin II Type 1 Receptor in Stabilizing the Inactive State

Author:

Miura Shin-ichiro1,Kiya Yoshihiro2,Kanazawa Takanori3,Imaizumi Satoshi2,Fujino Masahiro2,Matsuo Yoshino2,Karnik Sadashiva S.1,Saku Keijiro2

Affiliation:

1. Department of Molecular Cardiology (S.-i.M., S.S.K.), Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195

2. Department of Cardiology (S.-i.M., Y.K., S.I., M.F., Y.M., K.S.), Fukuoka University School of Medicine, Fukuoka 814-0180, Japan

3. Novartis Institute for BioMedical Research (T.K.), Tsukuba 300-2611, Japan

Abstract

AbstractAlthough the sartan family of angiotensin II type 1 (AT1) receptor blockers (ARBs), which includes valsartan, olmesartan, and losartan, have a common pharmacophore structure, their effectiveness in therapy differs. Although their efficacy may be related to their binding strength, this notion has changed with a better understanding of the molecular mechanism. Therefore, we hypothesized that each ARB differs with regard to its molecular interactions with AT1 receptor in inducing inverse agonism. Interactions between valsartan and residues Ser105, Ser109, and Lys199 were important for binding. Valsartan is a strong inverse agonist of constitutive inositol phosphate production by the wild-type and N111G mutant receptors. Substituted cysteine accessibility mapping studies indicated that valsartan, but not losartan, which has only weak inverse agonism, may stabilize the N111G receptor in an inactive state upon binding. In addition, the inverse agonism by valsatan was mostly abolished with S105A/S109A/K199Q substitutions in the N111G background. Molecular modeling suggested that Ser109 and Lys199 bind to phenyl and tetrazole groups of valsartan, respectively. Ser105 is a candidate for binding to the carboxyl group of valsartan. Thus, the most critical interaction for inducing inverse agonism involves transmembrane (TM) V (Lys199) of AT1 receptor although its inverse agonist potency is comparable to olmesartan, which bonds with TM III (Tyr113) and TM VI (His256). These results provide new insights into improving ARBs and development of new G protein-coupled receptor antagonists.

Publisher

The Endocrine Society

Subject

Endocrinology,Molecular Biology,General Medicine

Cited by 70 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3